Patients, caregivers, and others interested in lung cancer research gathered at The Ven Embassy Row in Washington, DC to hear about treatment innovations and gain a better understanding of the science involved. LCRF Together DC offered an opportunity for the community to connect while learning about promising therapies for treating lung cancer.
Dr. Benjamin Levy, Johns Hopkins Sidney Kimmel Cancer Center, and LCRF Chief Scientific Officer Dr. Antoinette Wozniak, had a lively discussion with the group and moderator Dr. Joan Schiller. Dr. Schiller is a member of LCRF’s board and the liaison for its Education & Engagement Committee, and Dr. Levy serves on the committee as well.
The panel addressed topical areas including as gene mutations, biomarker testing, liquid biopsies, personalized medicine, immunotherapy, and antibody drug conjugates. “Dr. Levy’s remarks about liquid biopsies especially seemed to capture the audience’s attention,” said Courtney Brandt, who directs LCRF’s educational programs. “A lot of us left the event thinking about his words: ‘the future is blood – blood is beautiful.”
See photos of the event and watch a few clips below.
Special thanks to our event sponsors for making this program possible!
Genentech, a member of the Roche Group | Bristol Meyers-Squibb | Gilead Sciences, Inc. | Arcus Biosciences | AbbVie | Mirati Therapeutics
